YANTAI, China, Jan. 12, 2024 /PRNewswire/ — RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted…
RemeGen’s RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients
This post was originally published on this site